Säveland H, Hillman J, Brandt L, Edner G, Jakobsson K E, Algers G
Department of Neurosurgery, University Hospitals of Lund, Linköping, Stockholm, Sweden.
J Neurosurg. 1992 May;76(5):729-34. doi: 10.3171/jns.1992.76.5.0729.
The present prospective study, with participation of five of the six neurosurgical centers in Sweden, was conducted to evaluate the overall management results in patients with aneurysmal subarachnoid hemorrhage (SAH). The participating centers covered 6.93 million (81%) of Sweden's 8.59 million inhabitants. All patients with verified aneurysmal SAH admitted between June 1, 1989, and May 31, 1990, were included in this prospective study. A uniform management protocol was adopted involving ultra-early referral, earliest possible surgery, and aggressive anti-ischemic treatment. A total of 325 patients were admitted during the study period, 69% within 24 hours after hemorrhage. On admission, the patients were graded according to the scale of Hunt and Hess: 43 patients (13%) were classified in Grade I, 119 (37%) in Grade II, 53 (16%) in Grade III, 76 (23%) in Grade IV, and 34 (11%) in Grade V. Nimodipine was administered to 269 of the 325 patients: intravenously in 218, orally in 15, and intravenously followed by orally in 36. At follow-up examination 3 to 6 months after SAH, 183 patients (56%) were classified as having made a good neurological recovery, 73 patients (23%) suffered some morbidity, and 69 (21%) were dead. Surgery was performed in 276 (85%) of the patients; emergency surgery with evacuation of an associated intracerebral hematoma was carried out in 30 patients. Early surgery (within 72 hours after SAH) was performed in 170 individuals, intermediate surgery (between Days 4 and 6 post-SAH) in 29 patients, and late surgery (Day 7 or later after SAH) in 47 individuals. Of 145 patients with supratentorial aneurysms who were preoperatively in Hunt and Hess Grades I to III and who were treated within 72 hours, 81% made a good recovery; in 5.5% of patients, the unfavorable outcome was ascribed to delayed ischemia. It is concluded that, among patients with all clinical grades and aneurysmal locations, almost six of 10 SAH victims referred to a neurosurgical unit can be saved and can recover to a normal life.
本前瞻性研究由瑞典六个神经外科中心中的五个参与进行,旨在评估动脉瘤性蛛网膜下腔出血(SAH)患者的整体治疗效果。参与的中心覆盖了瑞典859万居民中的693万(81%)。所有在1989年6月1日至1990年5月31日期间确诊为动脉瘤性SAH并入院的患者均纳入本前瞻性研究。采用了统一的治疗方案,包括超早期转诊、尽早手术以及积极的抗缺血治疗。研究期间共收治325例患者,69%在出血后24小时内入院。入院时,根据Hunt和Hess分级量表对患者进行分级:43例(13%)为I级,119例(37%)为II级,53例(16%)为III级,76例(23%)为IV级,34例(11%)为V级。325例患者中有269例使用了尼莫地平:218例静脉给药,15例口服给药,36例先静脉给药后口服给药。在SAH后3至6个月的随访检查中,183例(56%)患者被判定神经功能恢复良好,73例(23%)患者有一些并发症,69例(21%)患者死亡。276例(85%)患者接受了手术;30例患者进行了急诊手术并清除了相关的脑内血肿。170例患者在早期(SAH后72小时内)进行了手术,29例在中期(SAH后第4至6天)进行了手术,47例在晚期(SAH后第7天或更晚)进行了手术。145例幕上动脉瘤患者术前Hunt和Hess分级为I至III级且在72小时内接受治疗,其中81%恢复良好;5.5%的患者预后不良归因于迟发性缺血。研究得出结论,在所有临床分级和动脉瘤位置的患者中,转诊至神经外科的SAH患者中几乎十分之六能够获救并恢复正常生活。